Breaking News

Infineon Technologies to Buy International Rectifier for $3 Billion

The European CyberKnife Center Munich is celebrating its 5,000th patient treatment using the CyberKnife® System

 The European CyberKnife Center Munich is celebrating its 5,000th patient  treatment using the CyberKnife® System  Where experience and state-of-the-art technology meet  SUNNYVALE, Calif., April 7, 2014 /CNW/ - Accuray Incorporated (Nasdaq: ARAY)  announced today that the European CyberKnife Center Munich-Grosshadern (ECZM)  has performed 5,000 CyberKnife® treatments since June 2005. The center uses a  CyberKnife M6™ System from the latest generation series, the most advanced  robotic radiosurgery system in the world. Patients of the center benefit from  a treatment option that offers enhanced stereotactic radiosurgery/stereotactic  body radiation therapy (SRS/SBRT): tumors are treated non-invasively with  precisely delivered high doses of radiation.  The European CyberKnife Center, in partnership with the University Hospital of  Munich-Großhadern, offers almost 10 years of experience with this  state-of-the-art technology. "The treatment with the CyberKnife System offers  a number of benefits compared to surgery: no anesthesia, no pain and minimal  side effects," explains Prof. Alexander Muacevic, who founded the treatment  center together with his colleague Prof. Berndt Wowra in 2005. The CyberKnife  System is used for tumors anywhere in the body. Prof. Muacevic added, "We  treat brain tumors as well as tumors in the spine, the lung, the liver, and  the prostate with good clinical outcomes. This remarkable technology is based  on an integration of the latest developments in the field of image guidance,  computer sciences and robotic radiation delivery."  The CyberKnife System features a compact linear accelerator mounted on a  robotic arm. It is the only system that automatically adjusts the beam  delivery to motion during treatment in real-time. This precision is essential  to deliver high doses to the target area while simultaneously minimizing  radiation exposure to surrounding healthy tissue and organs. The CyberKnife M6  System can deliver non-coplanar, non-isocentric beams from a wider number of  angles around the patient, with the ability to follow tumors in real-time  throughout the treatment. This provides clinicians the confidence to reduce  margins for every disease that is treatable with the CyberKnife System.  "Accuray is proud of the cooperation with the European CyberKnife Center.  We  congratulate the European CyberKnife team on this tremendous achievement, and  are pleased our precise, innovative tumor treatments are available to patients  in such a highly experienced center," said Lionel Hadjadjeba, SVP Business  International & GM EIMEA, Accuray International.  About Accuray Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology  company that develops, manufactures and sells precise, innovative treatment  solutions that set the standard of care with the aim of helping patients live  longer, better lives. The company's leading-edge technologies deliver the full  range of radiation therapy and radiosurgery treatments.  About the European CyberKnife Center, Germany Besides the clinical and  scientific cooperation with the Neurosurgical Department and the Institute of  Clinical Radiology of the University of Munich, the CyberKnife Center Munich  collaborates internationally with colleagues around the world. Close  partnerships exist with the University Hospital Charite Berlin  ( and the Stanford University, California/ USA.  Furthermore a scientific partnership is maintained with the Institute of  Robotics and Cognitive Systems of the University Lübeck (Director: Professor  Dr. Schweikard) where essential parts of the CyberKnife System have been  developed (navigation software). Via the most modern telecommunication systems  special cases are discussed with other dedicated experts around the world.  Also, scientific projects are conducted on an international basis.Being part  of the Radiosurgery Society's ( Board of Directors we  put great effort in the development of internationally appreciated standards  for treatment, education and quality control.  Safe Harbor Statement  Statements made in this press release that are not  statements of historical fact are forward-looking statements and are subject  to the "safe harbor" provisions of the Private Securities Litigation Reform  Act of 1995. Forward-looking statements in this press release relate, but are  not limited to, the level of development of new technologies, clinical  experience, clinical applications, clinical results, patient experiences and  outcomes, and the company's leadership position in radiation oncology  innovation and technology. Forward-looking statements are subject to risks and  uncertainties that could cause actual results to differ materially from  expectations, including risks detailed under the heading "Risk Factors" in the  company's report on Form 10-K filed on August 29, 2013, the company's report  on Form 10-Q filed on February 7, 2014, and as updated periodically by the  company's other filings.  Forward-looking statements speak only as of the date the statements are made  and are based on information available to the company at the time those  statements are made and/or management's good faith belief as of that time with  respect to future events. Accuray assumes no obligation to update  forward-looking statements to reflect actual performance or results, changes  in assumptions or changes in other factors affecting forward-looking  information, except to the extent required by applicable securities laws.  Accordingly, investors should not place undue reliance on any forward-looking  statements.    SOURCE  Accuray Incorporated  Sancie Nakarat, Sr Marketing Communications Manager, Europe, Tel + 33 (0) 1 55  23 20 20,; Laura Scally, MSLGROUP, +1 (781) 684-0770,  To view this news release in HTML formatting, please use the following URL:  CO: Accuray Incorporated ST: California NI: HEA MTC CPR ELE NP  
Press spacebar to pause and continue. Press esc to stop.